TickerTalks
Browse all tickers →
TickerTalks›$ALHC
ALALHC

Alignment Healthcare, Inc.

$ALHC·$2.6B·Medical - Healthcare Plans·Healthcare
$12.61-1.2%YTD-36.2%1Y-22.9%
Price updated 2d ago·X counts updated 2h ago
ALALHC
$ALHCAlignment Healthcare, Inc.
$12.61-1.18%51 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $ALHC on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

51X posts · last 7 days
Aug 31Sep 13
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $ALHC's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 59% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ALHC — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-09-12

Falling on heavy selling — points lower unless it turns around.

Medicare Advantage margin thesis in doubt, class-action noise stacked on top

Alignment Healthcare is the tech-forward Medicare Advantage insurer that spent the summer surrendering the growth-and-margin story it was originally sold on, and the tape has not yet found its floor.

  • A cluster of Kaplan Fox and adjacent law-firm notices on 8-9 Sep announcing a potential securities-class-action investigation puts a legal overhang on an already re-rated equity
  • Q2 revenue of $1.34B against $1.24B the prior quarter is real growth, but consensus FY26 sits at $5.21B revenue on just $0.18 EPS across six analysts — the top line is compounding while margins are barely there
  • The 10 Sep Fifth Annual Seniors Survey reinforces the demographic tailwind that got MA insurers rerated in the first place; that tailwind has stopped being enough on its own
  • The 8 Sep Hoag Health System expansion in Orange County is a positive network step, but too small to reset a margin-thesis break of this magnitude

Watch the medical-loss-ratio trend and any resolution of the securities investigation; without both, the current base looks more like a way-station than a bottom.

What to watch: MLR trend, resolution of the class-action investigation, and any commentary on 2027 MA bid competitiveness

On the calendar: 2026-11-05 — Q3 2026 earnings (approx.)

thin x sample

Read the AI verdict on $ALHC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Technology-driven Medicare Advantage insurer operating in California, North Carolina, and Nevada with a consumer-focused care model.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Plans sits in its cycle right now — and what that implies for $ALHC.

Medical - Healthcare Plans · Healthcare

CVS explicitly flagged elevated medical cost trends this week, confirming ongoing managed-care pressure from specialty drug inflation and utilization recovery. Medicare Advantage star-rating reductions are compressing insurer margins heading into the 2027 rate-notice cycle.

What this means for $ALHC

Partial — Alignment Healthcare Medicare Advantage; value-based care model, technology-first MA, small-scale growth story.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.9%YTD
+15.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
78.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
9.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
1.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
20.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
5.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$0.17$0.13+31.8%
Q1 2026Apr 30, 2026$0.05$0.01+400.0%
Q4 2025Feb 26, 2026$-0.05$-0.15+66.7%
Q3 2025Oct 30, 2025$0.02$-0.01+300.0%
Next earningsThu, Oct 29·consensus EPS $-0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$1.3B+31.6%-10.8%3.2%$0.17$-9.9M
Q1 FY26$1.2B+33.3%11.7%1.3%$0.06$121.3M
Q4 FY25$1.0B+44.4%12.2%-1.0%$-0.05$-66.6M
Q3 FY25$993.7M+43.5%12.6%0.8%$0.02$160.8M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$5.2B$5.2B – $5.2B$0.18$0.16 – $0.209
FY27$6.5B$6.3B – $6.7B$0.43$0.35 – $0.569
FY28$8.1B$7.6B – $8.6B$0.75$0.56 – $0.8910
FY29$10.4B$10.2B – $10.7B$1.28$1.24 – $1.335
FY30$13.1B$12.8B – $13.5B$1.71$1.66 – $1.775

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.2%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-23.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-33.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 187.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.115-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 11Maroney Dawn ChristinePresident122.7K sh$1.6MSellSep 11John E KaoCEO385.3K sh$4.9MSellSep 10John E KaoCEO172.6K sh$2.2MSellAug 14Maroney Dawn ChristinePresident5.0K sh$70KSellAug 10John E KaoCEO298.0K sh$4.1MSellJul 15Maroney Dawn ChristinePresident177.1K sh$3.7MSellJul 10John E KaoCEO298.0K sh$5.9MSellJul 1Joseph S KonowieckiEVP, Corporate Affairs25.0K sh$600KSellJun 26Joseph S KonowieckiEVP, Corporate Affairs25.0K sh$575KSellJun 18Joseph S KonowieckiEVP, Corporate Affairs25.0K sh$550K
1–10 of 32
+ 6 other (3 awards · 2 gifts · 1 exempt) in window

See when $ALHC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 98-K — Item 5.07: Shareholder vote
AI summary

Alignment Healthcare, Inc. (Nasdaq: ALHC) filed its 2026 annual meeting voting results on June 9, 2026. Deloitte & Touche LLP was ratified as independent auditor (194,030,577 for / 13,893 against / 68,522 abstain). The say-on-pay advisory vote passed (169,068,300 for / 8,701,941 against / 542,191 abstain). All proposals passed; the say-on-pay result (~5% dissent) shows modest shareholder opposition to executive compensation but is within normal range — routine annual meeting disclosure.

3New insider — initial holdingsJun 23
AI summary

Shane J. Hochradel, Chief Operations Officer of Alignment Healthcare, Inc. (ALHC), filed this Form 3 as initial statement of beneficial ownership as of June 1, 2026. Tables I and II show no non-derivative or derivative securities beneficially owned. This is an administrative insider registration filing upon appointment to COO; the absence of listed securities likely reflects that equity awards had not yet been granted or vested at the time of filing.

3New insider — initial holdingsMay 203
8-KCharter amendmentMay 128-K — Item 5.03: Charter amendment · Item 7.01: Press release / Reg FD
+ 15 other (7 13Gs · 3 proxys · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Alignment Health's Fifth Annual Survey Finds Seniors Falling Further Behind: Aging in Place Challenges Continue to Rise as Support Gaps Widenglobenewswire.com·4d agoKaplan Fox Reminds Alignment Healthcare, Inc. (ALHC) Investors of an Investigation into Potential Securities Law Violationsnewsfilecorp.com·4d agoKaplan Fox Reminds Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors to Protect Their Rights Amid a Securities Investigationglobenewswire.com·5d agoKaplan Fox & Kilsheimer LLP Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violationsnewsfilecorp.com·5d agoAlignment Health Plan and Hoag Health System Increase Access to Award-Winning Care for Orange County Seniorsglobenewswire.com·6d ago

More in Medical - Healthcare Plans

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OSCR$UNH$CLOV$CVS$ELV$CNC$MOH$CI
Voices on X · last 7 days

No standout posts about $ALHC on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport